Browsing Tag
HER2-positive breast cancer
7 posts
How ALX Oncology Holdings Inc is repositioning its clinical strategy to achieve pivotal trial readiness by end-2026
ALX Oncology outlines its 2026 pivotal trial roadmap as ASPEN-09 expands and $150m funding extends runway. Read what changes next.
Why predictive biomarkers may determine ALX Oncology’s competitive viability in HER2-positive breast cancer
Find out why CD47 biomarkers could determine ALX Oncology’s ability to compete in HER2-positive breast cancer and what risks remain for evorpacept.
AstraZeneca, Daiichi Sankyo score tenth BTD for Enhertu in early HER2 disease
AstraZeneca and Daiichi Sankyo’s Enhertu earns FDA breakthrough tag in early breast cancer. Find out what this means for HER2 treatment strategy in 2025.
Kazia Therapeutics (NASDAQ: KZIA) unveils immune-boosting effects of paxalisib in advanced breast cancer at SABCS 2025
Find out how Kazia Therapeutics’ paxalisib is breaking new ground in breast cancer immunotherapy. Read the latest clinical insights from SABCS 2025.
ATNM-400 from Actinium Pharmaceuticals (ATNM) shows breakthrough promise in resistant breast cancer
Actinium’s ATNM-400 shows potent activity in resistant breast cancer and TNBC. Find out what the new SABCS 2025 data reveal about this radiopharma candidate.
Major oncology milestone as Organon and Henlius secure FDA approval for POHERDY, the first U.S. biosimilar to PERJETA
Find out how FDA approval of POHERDY, the first U.S. biosimilar to PERJETA, may transform HER2-positive breast cancer treatment costs and patient access.
EirGenix signs global licensing deal with Sandoz for second HER2 biosimilar EG1206A
EirGenix signs a USD 152M global deal with Sandoz for its Perjeta biosimilar EG1206A after FDA/EMA nod. Find out what this means for the HER2 drug race.